Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis.

Jiang Q, Jiang XH, Zheng MH, Jiang LM, Chen YP, Wang L.

Eur J Gastroenterol Hepatol. 2008 Nov;20(11):1064-70. doi: 10.1097/MEG.0b013e328302f470. Review.

PMID:
19047837
2.

Rifaximin for the treatment of hepatic encephalopathy.

Lawrence KR, Klee JA.

Pharmacotherapy. 2008 Aug;28(8):1019-32. doi: 10.1592/phco.28.8.1019. Review.

PMID:
18657018
3.

Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis.

Eltawil KM, Laryea M, Peltekian K, Molinari M.

World J Gastroenterol. 2012 Feb 28;18(8):767-77. doi: 10.3748/wjg.v18.i8.767. Review.

4.

Systematic review with network meta-analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy.

Zhu GQ, Shi KQ, Huang S, Wang LR, Lin YQ, Huang GQ, Chen YP, Braddock M, Zheng MH.

Aliment Pharmacol Ther. 2015 Apr;41(7):624-35. doi: 10.1111/apt.13122. Review.

5.

Nonabsorbable disaccharides for hepatic encephalopathy.

Als-Nielsen B, Gluud LL, Gluud C.

Cochrane Database Syst Rev. 2004;(2):CD003044. Review. Update in: Cochrane Database Syst Rev. 2016;4:CD003044.

PMID:
15106187
6.

Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?

Gluud LL, Dam G, Borre M, Les I, Cordoba J, Marchesini G, Aagaard NK, Vilstrup H.

Metab Brain Dis. 2013 Jun;28(2):221-5. doi: 10.1007/s11011-012-9372-0. Review.

PMID:
23275147
7.

Rifaximin for treatment of hepatic encephalopathy.

Maclayton DO, Eaton-Maxwell A.

Ann Pharmacother. 2009 Jan;43(1):77-84. doi: 10.1345/aph.1K436. Review.

PMID:
19092143
8.

Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy.

Kimer N, Krag A, Møller S, Bendtsen F, Gluud LL.

Aliment Pharmacol Ther. 2014 Jul;40(2):123-32. doi: 10.1111/apt.12803. Review.

9.

Disaccharides in the treatment of hepatic encephalopathy.

Sharma P, Sharma BC.

Metab Brain Dis. 2013 Jun;28(2):313-20. doi: 10.1007/s11011-013-9392-4. Review.

PMID:
23456517
10.

Rifaximin: new therapeutic indication and future directions.

Rivkin A, Gim S.

Clin Ther. 2011 Jul;33(7):812-27. doi: 10.1016/j.clinthera.2011.06.007. Review.

PMID:
21741091
11.

Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials.

Als-Nielsen B, Gluud LL, Gluud C.

BMJ. 2004 May 1;328(7447):1046. Review.

12.

Combination therapy for the treatment and prevention of hepatic encephalopathy.

Mohammad RA, Regal RE, Alaniz C.

Ann Pharmacother. 2012 Nov;46(11):1559-63. doi: 10.1345/aph.1R146. Review.

PMID:
23092866
13.

Management of hepatic encephalopathy in the hospital.

Leise MD, Poterucha JJ, Kamath PS, Kim WR.

Mayo Clin Proc. 2014 Feb;89(2):241-53. doi: 10.1016/j.mayocp.2013.11.009. Review.

14.

Probiotics for patients with hepatic encephalopathy.

McGee RG, Bakens A, Wiley K, Riordan SM, Webster AC.

Cochrane Database Syst Rev. 2011 Nov 9;(11):CD008716. doi: 10.1002/14651858.CD008716.pub2. Review.

PMID:
22071855
15.

Rifaximin for Irritable Bowel Syndrome: A Meta-Analysis of Randomized Placebo-Controlled Trials.

Li J, Zhu W, Liu W, Wu Y, Wu B.

Medicine (Baltimore). 2016 Jan;95(4):e2534. doi: 10.1097/MD.0000000000002534. Review.

16.

Treatment options for hepatic encephalopathy.

Schiano TD.

Pharmacotherapy. 2010 May;30(5 Pt 2):16S-21S. doi: 10.1592/phco.30.pt2.16S. Review.

PMID:
20412036
17.

Rifaximin for the treatment of hepatic encephalopathy.

de Melo RT, Charneski L, Hilas O.

Am J Health Syst Pharm. 2008 May 1;65(9):818-22. doi: 10.2146/ajhp070298. Review.

PMID:
18436728
18.

Update on management of patients with overt hepatic encephalopathy.

Chacko KR, Sigal SH.

Hosp Pract (1995). 2013 Aug;41(3):48-59. doi: 10.3810/hp.2013.08.1068. Review.

PMID:
23948621
19.
20.

Should We Treat Minimal/Covert Hepatic Encephalopathy, and with What?

Henderson PK, Herrera JL.

Clin Liver Dis. 2015 Aug;19(3):487-95. doi: 10.1016/j.cld.2015.04.002. Review.

PMID:
26195203
Items per page

Supplemental Content

Support Center